Protein ID'd Inside Cells During MS Inflamation

From the National Multiple Sclerosis Society Website

Novel Protein Identified Inside Cells During MS Inflammation May Help Explain Nerve Damage

April 27, 2017

Researchers from the University of Alberta in Canada report that levels of Rab32 – a protein that directs traffic between cell organs – are increased in sites of active inflammation in brain tissue obtained from people with MS and in mouse models of MS-like disease. This increase was linked to the destruction of nerve cells. If the results are confirmed, this knowledge could explain part of the neurodegenerative process that leads to progression of disability in MS and could be a target for development of effective MS treatments.

Endoplasmic Reticulum Plays Role In Multiple Sclerosis Progression Dan Modano  April 25, 2017

A new cellular mechanism that may cause multiple sclerosis has been discovered by researchers. The finding represents a major new discovery towards finding the cause of multiple sclerosis (MS), potentially paving the way for research to investigate new treatments.

Multiple sclerosis affects around 2.5 million people around the world. Typically, people are diagnosed in their 20s and 30s, and it is more common in women than men. Professor Paul Eggleton, of the University of Exeter Medical School, said:

“Multiple sclerosis can have a devastating impact on people’s lives, affecting mobility, speech, mental ability and more. So far, all medicine can offer is treatment and therapy for the symptoms – as we do not yet know the precise causes, research has been limited. Our exciting new findings have uncovered a new avenue for researchers to explore. It is a critical step, and in time, we hope it might lead to effective new treatments for MS.”

MITOCHONDRIA SUSPECTED

The cause of MS has so far been a mystery. It is known that the disease causes the body’s own immune system to attack myelin – the fatty “sheaths” that protect nerves in the brain and spinal cord.

This leads to brain damage, a reduction in blood supply and oxygen and the formation of lesions in the body. Symptoms can be wide-ranging, and can include muscle spasms, mobility problems, pain, fatigue, and problems with speech.

Scientists have long suspected that mitochondria, the energy-creating “powerhouse” of the cell, play a link in causing multiple sclerosis.

The international team, involving the University of Exeter Medical School and the University of Alberta, was the first to combine clinical and laboratory experiments to explain how mitochondria become defective in people with MS. Using human brain tissue samples , they found that a protein called Rab32 is present in large quantities in the brains of people with MS, but is virtually absent in healthy brain cells.

RAB32 AND ENDOPLASMIC RETICULUM STRESS

Endoplasmic Reticulum

Blausen.com staff (2014). WikiJournal of Medicine 1. DOI:10.15347/wjm/2014.010. CC BY 3.0

Where Rab32 is present, the team discovered that the endoplasmic reticulum (ER), a part of the cell that stores calcium, gets too close to the mitochondria. The resulting miscommunication with the calcium supply triggers the mitochondria to misbehave, ultimately causing toxicity for brain cells people with MS.

Researchers do not yet know what causes an unwelcome influx of Rab32 but they believe the defect could originate at the base of the ER organelle. The finding will enable scientists to search for effective treatments that target Rab32 and embark on determining whether there are other proteins that may pay a role in triggering MS.

Dr David Schley, Research Communications Manager at the MS Society, said:

“No one knows for sure why people develop MS and we welcome any research that increases our understanding of how to stop it. There are currently no treatments available for many of the more than 100,000 people in the UK who live with this challenging and unpredictable condition. We want people with MS to have a range of treatments to choose from, and be able to get the right treatment at the right time.”

The research was supported by the Canadian Institutes of Health Research and MS Society of Canada, along with a Royal Devon and Exeter Foundation Trust Hospital grant.